CR20130572A - Formulaciones de liberación sostenida de paracetamol - Google Patents

Formulaciones de liberación sostenida de paracetamol

Info

Publication number
CR20130572A
CR20130572A CR20130572A CR20130572A CR20130572A CR 20130572 A CR20130572 A CR 20130572A CR 20130572 A CR20130572 A CR 20130572A CR 20130572 A CR20130572 A CR 20130572A CR 20130572 A CR20130572 A CR 20130572A
Authority
CR
Costa Rica
Prior art keywords
sustained release
paracetamol
release formulations
release phase
paracetamol sustained
Prior art date
Application number
CR20130572A
Other languages
English (en)
Inventor
Carla Valenti Buan
Dongzhou Liu
Kanji Meghpara
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CR20130572A publication Critical patent/CR20130572A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención presente está dirigida a una composiciónfarmacéutica de liberación sostenida de dos veces al día de paracetamol que tiene una fase de liberación inmediata de paracetamol y una 5 fase de liberación sostenida de paracetamol, dicha composición tiene propiedades farmacocinéticas únicas y ventajosas y una composición farmacéutica que comprende sólo una fase de liberación sostenida de paracetamol que tienepropiedades farmacocinéticas únicas y ventajosas.
CR20130572A 2011-05-06 2013-11-06 Formulaciones de liberación sostenida de paracetamol CR20130572A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161483320P 2011-05-06 2011-05-06

Publications (1)

Publication Number Publication Date
CR20130572A true CR20130572A (es) 2014-03-20

Family

ID=47139543

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130572A CR20130572A (es) 2011-05-06 2013-11-06 Formulaciones de liberación sostenida de paracetamol

Country Status (19)

Country Link
US (1) US20140065213A1 (es)
EP (1) EP2704697B1 (es)
CN (1) CN103648486A (es)
AP (1) AP3878A (es)
AU (1) AU2012253834B2 (es)
BR (1) BR112013028668A2 (es)
CA (1) CA2835330A1 (es)
CL (1) CL2013003176A1 (es)
CO (1) CO6801767A2 (es)
CR (1) CR20130572A (es)
DO (1) DOP2013000258A (es)
EA (1) EA201391643A1 (es)
GT (1) GT201300270A (es)
MX (1) MX2013012918A (es)
NI (1) NI201300116A (es)
SG (1) SG194605A1 (es)
TW (1) TW201306881A (es)
WO (1) WO2012154563A1 (es)
ZA (1) ZA201308316B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TW201507726A (zh) * 2013-05-10 2015-03-01 Glaxosmithkline Llc 菸鹼菱形錠配製物
BE1021194B1 (nl) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba Paracetamol tabletten
EA033298B1 (ru) 2015-03-03 2019-09-30 Саниона А/С Комбинированная лекарственная форма тезофензина и метопролола
BE1023116B1 (nl) * 2015-07-24 2016-11-23 Nordic Specialty Pharma Bvba Paracetamol omvattend preparaat met vertraagde en aanhoudende afgifte

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AUPN940796A0 (en) * 1996-04-23 1996-05-16 F.H. Faulding & Co. Limited Taste masked pharmaceutical compositions
CA2301883A1 (en) * 1997-09-11 1999-03-18 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
ATE286725T1 (de) * 1998-10-01 2005-01-15 Novartis Pharma Gmbh Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
GB0114069D0 (en) * 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
WO2004004696A1 (en) * 2002-07-05 2004-01-15 Temrel Inc. Controlled release composition
KR20120106757A (ko) * 2003-09-26 2012-09-26 알자 코포레이션 오피오이드 및 비오피오이드 진통제의 제어 방출 제제
US20080031901A1 (en) * 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
BRPI0512756A (pt) * 2004-07-07 2008-04-08 Aft Pharmaceuticals Ltd composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
EP2271330A1 (en) * 2008-02-01 2011-01-12 Abbott Laboratories Extended release hydrocodone acetaminophen and related methods and uses thereof
CN102105136B (zh) * 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
EA023149B1 (ru) * 2008-10-27 2016-04-29 Алза Корпорейшн Фармацевтическая композиция, содержащая ацетаминофен и комплекс трамадола с каррагинаном, лекарственная форма, способ ее изготовления и применение комплекса трамадола с каррагинаном для лечения боли
US8021420B2 (en) * 2009-03-12 2011-09-20 Medtronic Vascular, Inc. Prosthetic valve delivery system
PL399450A1 (pl) * 2009-08-31 2013-01-21 Depomed, Inc Utrzymujace sie w zoladku kompozycje farmaceutyczne do natychmiastowego i przedluzonego uwalniania acetaminofenu

Also Published As

Publication number Publication date
CL2013003176A1 (es) 2014-07-04
ZA201308316B (en) 2014-07-30
NI201300116A (es) 2014-11-13
GT201300270A (es) 2014-12-16
MX2013012918A (es) 2013-11-21
CA2835330A1 (en) 2012-11-15
CN103648486A (zh) 2014-03-19
EA201391643A1 (ru) 2014-07-30
SG194605A1 (en) 2013-12-30
WO2012154563A1 (en) 2012-11-15
US20140065213A1 (en) 2014-03-06
CO6801767A2 (es) 2013-11-29
AP2013007224A0 (en) 2013-11-30
AU2012253834A1 (en) 2013-12-05
EP2704697A1 (en) 2014-03-12
AU2012253834B2 (en) 2016-06-16
EP2704697A4 (en) 2015-01-07
TW201306881A (zh) 2013-02-16
BR112013028668A2 (pt) 2017-01-24
EP2704697B1 (en) 2018-09-12
NZ617198A (en) 2016-01-29
DOP2013000258A (es) 2014-07-15
AP3878A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
CY1125061T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει δροσπιρενονη για χρηση ως ενα αντισυλληπτικο
BR112014017021A8 (pt) inibidores de irak e usos dos mesmos
BR112013007362A2 (pt) composição farmacêutica
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
BR112015016930A2 (pt) formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
BR112015009228A2 (pt) soluções estáveis anti-inflamatórias e midriáticas livres de conservantes para injeção
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
GT201200284A (es) Composición farmacéutica
CY1119446T1 (el) Φαρμακοτεχνικες μορφες δαρουναβιρης
BR112015006731A2 (pt) combinações e usos das mesmas
CR20130572A (es) Formulaciones de liberación sostenida de paracetamol
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112014025041B8 (pt) Composição farmacêutica
EA201100286A1 (ru) Композиция кветиапина
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201291050A1 (ru) Комбинация лекарств с протеинсвязывающими пролекарствами
CO7131388A2 (es) Métodos de quelatos de oligonucleótidos
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
ES2415029A8 (es) Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24.
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b